Palvella Therapeutics Announces Positive Phase 3 Results for SELVA Clinical Trial

Palvella Therapeutics has announced successful topline results from its Phase 3 SELVA clinical trial evaluating QTORIN 3.9% Rapamycin Anhydrous Gel. The study successfully met its primary endpoint with high statistical significance, recording a p-value of less than 0.0001. The treatment demonstrated significant clinical improvement in patients suffering from microcystic lymphatic malformations, a rare and debilitating condition. This positive outcome represents a major milestone for the company, significantly increasing the probability of regulatory approval and future commercialization. The successful data is expected to pave the way for a regulatory submission to the FDA in the near future. Market analysts view these results as a bullish signal for the biotech sector, potentially impacting related instruments like the XBI and IBB ETFs.